ERBB2 and breast carcinoma: In contrast, the following pathology outcomes were positively associated with increased breast cancer mortality: higher tumor grade (p < 0.0001), negative ER status (p = 0.0086), negative PR status (p = 0.0086), positive Her-2/Neu status (p = 0.0137), absence of EIC (p = 0.0323), presence of LTE (p = 0.0004), increased tumor size (p < 0.0001), axillary lymph nodes (p < 0.0001), and abandonment or refusal of chemotherapy treatment (p < 0.0001) (Table 3).